Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Nelson

Showing results (451-460 of 521) with videos related to

Pageof 53
Sort By:
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
Obesity Research & Clinical Practice|November 5, 2018
Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research ConsortiumDominick J Lemas, Michelle I Cardel, Stephanie L Filipp, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Journal of Hepatology|January 1, 2020
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"Donna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3David R Nelson, Yves Benhamou, Wan-Long Chuang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.
Pageof 53

Showing results (451-460 of 521) with videos related to

Sort By:
Pageof 53
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
Obesity Research & Clinical Practice|November 5, 2018
Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research ConsortiumDominick J Lemas, Michelle I Cardel, Stephanie L Filipp, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Journal of Hepatology|January 1, 2020
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)"Donna M Evon, Souvik Sarkar, Jipcy Amador, et al.
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3David R Nelson, Yves Benhamou, Wan-Long Chuang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.
Pageof 53